Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Kambakamba (Giessen, Germany), K. Tello (Giessen, Germany), J. Axmann (Giessen, Germany), H. Gall (Giessen, Germany), A. Ghofrani (Giessen, Germany), S. Guth (Bad Nauheim, Germany), C. Wiedenroth (Bad Nauheim, Germany), M. Richter (Giessen, Germany). Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 3049

Member's Comments

No comment yet.

Related content which might interest you: Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 110s Year: 2004 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 637-648 Year: 2004 Chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – ME5 Chronic thromboembolic pulmonary hypertension Year: 2015 Chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (1) 1801915; 10.1183/13993003.01915-2018 Year: 2019 Chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – State of the art session: Pulmonary vascular diseases Year: 2018 Chronic thromboembolic pulmonary hypertension Source: Annual Congress 2007 - Update on venous thromboembolism Year: 2007 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003 Predictors of physical activity in pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension Year: 2019 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2007; 30: 922-927 Year: 2007